Rallybio Corp (RLYB)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 212 | 212 | 299 | 299 |
| Research and development | 6,074 | 5,725 | 8,240 | 12,946 |
| General and administrative | 4,195 | 4,157 | 4,125 | 4,388 |
| Total operating expenses | 10,269 | 9,882 | 12,365 | 17,334 |
| Loss from operations | -10,057 | -9,670 | -12,066 | -17,035 |
| Other income | 118 | 174 | 251 | 143 |
| Interest income | 523 | 644 | 986 | 1,143 |
| Total other income, net | 641 | 818 | 1,237 | 1,286 |
| Loss before equity in losses of joint venture | -9,416 | -8,852 | -10,829 | -15,749 |
| Loss on investment in joint venture | -287 | -587 | -637 | -487 |
| Net loss | -9,703 | -9,439 | -11,466 | -16,236 |
| Net unrealized loss on marketable securities | -30 | -21 | 240 | - |
| Other comprehensive loss | -30 | -21 | 240 | - |
| Comprehensive loss | -9,733 | -9,460 | -11,226 | -16,236 |
| Net loss per common share, basic (in dollars per share) | -0.22 | -0.21 | -0.26 | -0.37 |
| Net loss per common share, diluted (in dollars per share) | -0.22 | -0.21 | -0.26 | -0.37 |
| Weighted-average common shares outstanding, basic (in shares) | 44,841,140 | 44,774,602 | 44,593,221 | 44,128,059 |
| Weighted-average common shares outstanding, diluted (in shares) | 44,841,140 | 44,774,602 | 44,593,221 | 44,128,059 |